| MMP-9 activity plays a role in the invasiveness of BRI-JM01 and 4T1 mammary tumor cell lines. We used an EMT (epithelial to mesenchymal transition) microarray dataset generated from BRI-JM01 mouse mammary cancer cell line treated with TGF-β 24, 25 and extracted ~100 secreted and cell surface proteins. Using the screening method 26 a survival analysis for these proteins was preformed using the breast cancer microarray datasets 27, 28 . The expression levels of seven genes, i.e., matrix metalloproteinase 9 (MMP9) were significantly correlated with patient survival. Here we validated the role of MMP9 in the BRI-JM01 cells and used the MMP9 secreting 4T1 mouse mammary tumor cell line 29 as a positive control. (a) RTPCR confirmed that TGF-β induces an upregulation of MMP9 expression in both cell lines. Additional western blot (b) and zymogram (c) analysis of the conditioned medium of TGF-β treated BRI-JM01 and 4T1 cells showed that MMP9 ( ) is secreted and enzymatically active, respectively. (d) A functional role of MMP9 in EMT was demonstrated by exposing BRI-JM01 (top panels) and 4T1 (bottom panels) cells to TGF-β in the presence or absence of a specific MMP9 inhibitor (MMP9 Inh I) which significantly inhibited the TGF-β induced morphology change in BRI-JM01, and to a lesser extent in 4T1 cells (magnification 40x). In addition, the results of a Transwell invasion assay (e) showed that TGF-β induced BRI-JM01 (white bars) and 4T1 (black bars) cells to penetrate and transgress a Matrigel barrier. The presence of MMP9 inhibitor significantly reduced invasiveness and confirms MMP9's role in the invasive character of BRI-JM01 cells undergoing EMT as a result of TGF-β exposure. Results are shown as the average (+/-SEM) of two independent experiments carried out in triplicate. The table lists gene groups define by GO (Gene Ontology) terms, number of random microarray datasets (RDS) and the ratios of "good" and "bad" tumors in each RDS used for running the Multiple Survival Screening (MSS) algorithm to generate the NRC (National Research Council) gene signatures. "Good" and "bad" tumor patients represent the breast cancer patients whose tumors have not recurred and recurred, respectively, within 10 years after the removal of their primary tumors.
Supplementary Tables Supplementary
1 Number of genes of the gene group used for screening of the NRC signatures;
2 Number of samples in each random dataset (ratio of the "good" and "bad" samples); 3 Number of total samples in the original training set (ratio of the "good" and "bad" samples). 2. Classify the members of the survival gene pool using the functional annotation-clustering tool 30 . a. Assign survival genes to several non-exclusive gene groups based on selected GO (Gene Ontology) terms closely related to the development of cancer, such as cell cycle, apoptosis, immunological response and so on. The groups are called GO-term-defined gene sets. b. Retain only the gene sets whose size satisfies: 50 < size < 100.
Supplementary

For each GO-term-defined gene set retained in
Step 2, generate 1 million random gene sets (RGSs) each containing 30 genes from the GO-term-defined gene set.
4.
Generate m random datasets (RDSs) from the training set, maintaining the same ratio of "good" and "bad" tumors as in the original training set.
5. Screen the GO-term-defined gene sets. 9. Re-run steps 5 to 8 using another 1 million RGSs distinct from the first run. For each GOterm-defined gene set, if duplicate runs yield the same top 28 genes in step 8 then the top 30 genes from the second run will be used as a gene signature.
The testing algorithm for gene signatures. To validate the performance of the National
Research Council (NRC) gene signatures, we tested them in the training and testing datasets using the leave-one-out method. We combined the outcomes of 3 gene signatures to classify samples. For each dataset which contains n samples, the algorithm of testing for ER+ gene signatures is described below. This is a more detailed description of the algorithm shown schematically in Figure 2b of the main text.
For i=1:n (n is the number of samples)
1. Extract feature vectors from a given gene signature (such as NRC-1). a) V i,j = (g 1,i,j , g 2,i,j , …, g 30,i,j ) where g k,i,j is the expression value of the kth gene of NRC-j in the ith sample (k=1, 2, … 30, j=1, 2, 3). b) Calculate V i,j,g , the feature vector of shrunken class centroids extracted from the jth set of signature genes (NRC-j) and the relapse-free patient samples (excluding the ith one) and using PAMR method 31 . c) Calculate V i,j,b , the feature vector of shrunken class centroids extracted from the jth set of signature genes (NRC-j) and metastasis patient samples (excluding the ith one). 4. For the samples in the high-risk group determined by NRC-1, -2 and -3, we further classify them using NRC-4, NRC-5 and NRC-6 by running Steps 1-3. If a sample is assigned to the relapse free group by NRC-4, -5 and -6, the sample will be appended to the intermediate-risk group determined by NRC-1, -2 and -3. If not, the sample is assigned to a new high-risk group.
End
Application of the algorithm to testing of the ER-gene signatures involves running through steps 1-3 using NRC-j (j = 7, 8, 9) instead of 1 to 3 Also, due to the small size of the data sets, the intermediate-and high-risk groups are combined to form the high-risk group.
Comments on the MSS algorithm
Subgroups of tumor samples using PGS profiles. In breast cancer, ER status has been used as a clinical feature to classify the samples into ER+ and ER-subgroups. However, certain tumor types have no clear subgroup classification using either clinical features or molecular feature (i.e., gene expression profiles). In this situation, we propose to use the PGS (passed gene sets) profiles of the random training datasets (RDSs) to reveal features (i.e., clinical or molecular features) that could classify the samples into subgroups for MSS.
We used Chang's cohort (this set has rich clinical annotations of samples) as an example to illustrate the PGS-based method. We first generated PGS profiles for 72 RDSs of Chang's cohort (as described in the first part of Result section in the main text). Based on the PGS profiles, we could divide the RDSs into 2 groups (keeping the redundant samples in the groups): low PGS group (i.e., RDSs have less than 5-10% of the average PGSs across all RDSs) and high PGS group. We then conducted statistical tests (i.e., t-test for continuous data; Fisher's test for binary data) between the two groups using every clinical or molecular feature of the samples. We found that except for ER, other features did not show statistical trends for the differences between the two groups. For ER, the P-value was ~0.08, a modestly significant P-value. However, it suggests that ER could be a useful feature to group the samples before running MSS. We tested if ER is a good classifier. To do so, we randomly generated 6 RDSs in which all are ER+ samples, and another 6 RDSs in which all are ER-samples. We performed the survival screening on these RDSs using the 1x10 5 of RGSs (randomly generated gene sets) which were used to generate the PGS profiles for the 72 RDSs (see the main text). If one group has high PGSs and the other has low PGSs, it means that ER can be used to classify the samples into 2 subgroups, which, in turn, can be used for running MSS. As shown in the main text, ER is in fact a classifier for grouping samples for MSS.
Determination of the appropriate number of genes for a gene signature. The number of breast cancer signature genes ranges from several to a few hundred among the five well-known breast cancer gene signatures. Among these signatures, 70-gene signature and the 21-gene Oncotype DX are the most well-known ones. We decide to start from a larger set (70 genes) to refine the size of signature genes. Therefore, in the preliminary testing, we decided to use van 't Veer dataset 27 , which was used to generate the 70-gene signature, to generate another 70-gene signature by running MSS. van 't Veer's 70-genes were selected from 231 modulated genes 27 . We used these 231 modulated genes to generate 1 million of RGSs, in which each RGS contains 70 genes. Using Wang dataset 28 , we generated 72 RDSs. After running MSS, we took the topranked 70 genes, which have only a few genes overlapped with van 't Veer's 70-genes, to conduct survival testing in another independent dataset 32 (Miller dataset) . In the tests, we systemically removed genes, one-by-one, from the bottom of the 70 gene list. Interestingly, we found that the P-values for the survival analyses were not changed until the gene set was reduced to the top 28 genes. Upon removing more genes from this list, the P-values suddenly increased and fluctuated (Supplementary Figure S4a) . Based on these observations we decided to use 30 genes as the size of the NRC gene signatures. We also validated the gene size using NRC-1, -2, and -3 by systemically conducted the survival tests by removing genes, one-by-one, from the bottom of the genes in each signature. Removal of several genes from the bottom of the ranklists did not affect the P-values of the survival tests in testing dataset (Supplementary Figure  S4b) , suggesting that 30 is a reasonable size.
Gene group selection. In the MSS algorithm, we suggested selecting gene groups based on GO terms associated with cancer hallmarks. Normally most of the GO terms contain 60-80 genes. We realize that there are likely a number of cancer hallmark genes that are not known yet. Hence, our reliance on GO term annotation may result in lacking some important genes in our signatures. Nevertheless, this does not detract from the predictive value of our GO-term-derived signatures. One strategy to widen our net is to augment the GO terms with other information, such as, text mining of genes based on co-occurrence with cancer hallmark genes or stem cell genes in the same sentences of the PubMed abstracts, or perhaps to include genes that physically or genetically interact with cancer hallmark genes or stem cell genes. These associated genes might then be used for running MSS.
Number of random training datasets for MSS.
We use the NRC-1 signature to illustrate how we determined the size of random datasets. First we generated two sets (A and B) of 1 million RGSs from the cell cycle genes (see the main text) such that no any RGS is common between the two sets. Using the Wang dataset, we generated 5, 10, 15, 20, 25, 30, 35 and 40 sets of RDSs. For each set of RDSs, we ran MSS using the RGS Sets A and B and ranked the genes as described in MSS. Then we calculated gene overlapping ratio: the numbers of the common genes among the top 30 genes are divided by 30. We found that the top 29 genes are the same for the RDS sets with the sizes of 35 and 40. In order to further investigate these phenomena in details, we extend the same analyses by generating 14 sets of RDS i (i= 27 +j; j= 0, 1, 2,..13). To obtain robust results, such analyses have been conducted 100 times and the average gene overlapping ratios were calculated and plotted (Supplementary Figure S5) . As shown in Supplementary Figure S5 , gene overlapping ratios are stable when the RDS sets have the sizes above 30. We extended the same analysis to NRC-2 and -3. Similar results were obtained (Supplementary Figure S5) . Based on these observations, we decided on the somewhat arbitrary value of 36 in our own production runs because we had 36 compute-nodes available to us to run our calculations in parallel.
Cells, cell culture, antibodies and reagents. BRI-JM01 cells were isolated, characterized and cultured as described 24 . Mouse mammary 4T1 tumor cells were obtained from, and cultured according to the instructions of the ATCC. Human recombinant TGF-β1 (R&D Systems) and MMP9 Inhibitor I (Calbiochem) were reconstituted according to the manufacturer's instructions.
